Tag: Drug patent

The U.S. Food and Drug Administration (FDA) first approved generic versions of cinacalcet on March 8, 2018. This milestone introduced competition for the brand-name drug Sensipar, which had sales of $1.72 billion in 2017. The question of *when did cinacalcet go generic?* is pivotal for understanding patient access and cost.

Affecting nearly 16% of the population in the United States, migraine is a common and often debilitating neurological condition [1.8.3]. A key question for many is, is there a generic version of Ubrelvy available to make treatment more affordable? Currently, the answer is no [1.2.3].

As of late 2025, there is no generic equivalent of the brand-name drug Januvia (sitagliptin) available in the U.S. that is interchangeable with the original. The active ingredient in Januvia is sitagliptin, which has a key patent that expires in 2026, though a different generic sitagliptin formulation (Zituvio) is available.

As of late 2025, there is no generic form of Nextstellis available for prescription in the United States, as the brand-name medication remains under patent protection. Developed by Mithra and marketed by Mayne Pharma, this specific oral contraceptive is a brand-exclusive product.

While Latisse was first approved by the FDA in December 2008 [1.6.1], the answer to **when did Latisse go generic** is more complex. The first generic approvals appeared years before the final patents expired in 2024, offering a more affordable option for treating eyelash hypotrichosis [1.2.1, 1.2.3].

As of late 2024, the U.S. Food and Drug Administration (FDA) has approved Bimzelx (bimekizumab) for multiple conditions, including plaque psoriasis and psoriatic arthritis. However, Bimzelx is a biologic medication, and for that reason, there is currently no generic for Bimzelx.

In 2025, an estimated 18.3% of U.S. adults are currently experiencing or being treated for depression [1.8.1]. For many, a key question is affordability, which leads them to ask: **Has Viibryd gone generic?** The answer is yes, offering a more accessible treatment option.